|Videos|August 7, 2020
Expedited Programs for Drug Approvals
Advertisement
Pharmaceutical Executive’s Lisa Henderson interviews Todd Phillips, PharmD, of Cardinal Health Regulatory Sciences about FDA’s expedited programs and key elements to consider before using this pathway.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Boehringer Ingelheim Expands Immunology Pipeline With Preclinical Antibody Licensing Deal
2
Marty Makary Out as FDA Commissioner: Report
3
The Insight Gap: Biopharma’s Hidden Risk in the Race Against the Patent Cliff
4
From Consulting to Venture Capital: A Q&A with Gibb Witham, President of Hack The Box
5